AgomAb Therapeutics NV (AGMB)
Nasdaq: AGMB · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2024
Who owns AgomAb Therapeutics NV
As filed with the SECHolders of 5% or more
6
LSP 7 Cooperatieve U.A. holds 10.6% of Common Shares, no nominal value per share ("Common Shares"), as its SCHEDULE 13D filed Feb 17, 2026 says.
Directors and officers
13
report now, of 13 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
LSP 7 Cooperatieve U.A.
SCHEDULE 13D · filed Feb 17, 2026 · Common Shares, no nominal value per share ("Common Shares")
Fmr LLC
SCHEDULE 13G · filed Mar 6, 2026 · COMMON STOCK
Pontifax VI G.P. L.P.
SCHEDULE 13G · filed Apr 16, 2026 · Common Shares, no nominal value per share
Sanofi
SCHEDULE 13G · filed May 6, 2026 · Common Shares, no nominal value per share ("Common Shares")
Redmile Group, LLC
SCHEDULE 13G · filed May 15, 2026 · Common Shares, no nominal value per share
Cormorant Asset Management, LP
SCHEDULE 13G · filed May 15, 2026 · American Depositary Shares, each representing one common share, no nominal value per share
What AGMB reports owning in othersstakes of 5% or more, and other ties
AgomAb Therapeutics NV reports no stake in another company in the record.
Insider tradesForm 4
0sales
13purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$500,000bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 13 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Epstein David R | director | 0 | $0 | 0 | 8 | $300,000 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | 0 | $0 | 0 | 3 | $100,000 |
| Knotnerus Tim Jasper | Chief Executive Officer | 0 | $0 | 0 | 2 | $100,000 |